Table 1.
Clinical and molecular features in the whole cohort of IDHwt grade II gliomas (n = 47), in the subgroup of patients meeting the definition of “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma (grade IV)” (molecular GBM) (n = 29) and in the subgroup of patients not meeting this definition (n = 14)
| IDHwt Grade II Gliomas, Whole Cohort (n = 47) | IDHwt Grade II Gliomas Meeting the Definition of Molecular GBM (n = 29) | IDHwt Grade II Gliomas NOT Meeting the Definition of Molecular GBM (n = 14) | P-value* | |
|---|---|---|---|---|
| Age, y, median (range) | 55.0 (19.6–82.1) | 58.6 (20.8–82.1) | 34.5 (19.6–65.4) | 0.00057 |
| Male | 36/47 (77%) | 24/29 (83%) | 10/14 (71%) | 0.44 |
| Preoperative KPS, median (range) | 90 (70–100) | 90 (70–100) | 90 (70–100) | 0.83 |
| Tumor location | ||||
| Fronto-temporo-insular | 28/47 (60%) | 19/29 (66%) | 5/14 (36%) | 0.0055 |
| Fronto-callosal or parieto- callosal | 4/47 (9%) | 4/29 (14%) | 0/14 (0%) | |
| Other | 11/47 (23%) | 6/29 (21%) | 5/14 (36%) | |
| Thalamo-mesencephalic | 4/47 (9%) | 0/29 (0%) | 4/14 (29%) | |
| Extent of resection | ||||
| Biopsy | 27/44 (61%) | 19/28 (68%) | 7/12 (58%) | 0.88 |
| Partial resection | 9/44 (20%) | 5/28 (18%) | 2/12 (17%) | |
| Gross total resection | 8/44 (18%) | 4/28 (14%) | 3/12 (25%) | |
| Initial treatment | ||||
| Chemotherapy alone | 13/38 (34%) | 10/25 (40%) | 3/9 (33%) | 0.74 |
| Sequential radiochemotherapy | 7/38 (18%) | 5/25 (20%) | 1/9 (11%) | |
| Stupp protocol | 12/38 (32%) | 7/25 (28%) | 3/9 (33%) | |
| Radiotherapy alone | 1/38 (3%) | 0/25 (0%) | 0/9 (0%) | |
| Surveillance | 5/38 (13%) | 3/25 (12%) | 2/9 (22%) | |
| Radiological progression | ||||
| Infiltrative | 13/18 (72%) | 11/15 (73%) | 2/3 (67%) | 0.45 |
| Nodular enhancing | 5/18 (28%) | 4/15 (27%) | 1/3 (33%) | |
| Molecular profile | ||||
| TERT promoter mutation | 23/45 (51%) | 23/28 (82%) | 0/14 (0%) | <0.0001 |
| EGFR amplification | 4/43 (9%) | 4/26 (15%) | 0/14 (0%) | 0.28 |
| 7+ | 10/37 (27%) | 10/26 (38%) | 0/10 (0%) | 0.016 |
| 10- | 10/41 (24%) | 10/26 (38%) | 0/14 (0%) | 0.011 |
| 7+/−10 | 7/41 (17%) | 7/26 (27%) | 0/14 (0%) | 0.075 |
| 9p loss | 3/42 (7%) | 3/26 (12%) | 0/14 (0%) | 0.54 |
| CDKN2A deletion | 5/43 (12%) | 3/26 (12%) | 1/14 (7%) | 1 |
| Median OS, mo | 59.1 | 42.2 | 56.7 | 0.2 |
7+ = whole chromosome 7 gain; 9p = chromosome 9p; −10 = whole chromosome 10 loss; 7+/−10 = whole chromosome 7 gain and whole chromosome 10 loss; FU = follow-up. *P-values refer to the comparison between patients meeting the definition for molecular GBM and patients not meeting this definition; in bold statistically significant results.